Recombinant Anti-CD3 x Anti-IL2R Bispecific Antibody (Miniantibody) is a fusion protein of two scFv fragments combined with distinct specificity. One scFv of an anti-CD3 antibody variable domain is linked to another scFv of an anti-IL2R antibody variable domain by a flexible hinge region. This BsAb format has the decreased size and better penetration than conventional IgGs in the clinical diagnostics and potentially therapy. This BsAb can retarget T cells to tumor cells. It is designed for the research of Hodgkin lymphoma; Non-Hodgkin's lymphoma (NHL); Acute lymphocytic leukemia (ALL) therapy.